Moderna (MRNA) is set for three data readouts on its individualized neoantigen therapies, or INT, in the near term, serving as potential stock catalysts for the company, UBS Securities said in a Tuesday note.

The next major catalyst is the release of phase 3 data on melanoma at an international conference this fall, investors awaiting efficacy on recurrence-free survival and distant metastasis-free survival, the brokerage said.

Likely to follow is the phase 2 data on either renal cell carcinoma or muscle-invasive bladder cancer, potentially in 2027, according to UBS. The next readout is probably a phase 3 update on adjuvant non-small cell lung cancer, the investment firm added.

UBS has a neutral rating and $150 price target on Moderna.

Price: 137.50, Change: -2.83, Percent Change: -2.02